Company: PFSA
Filing Date: 2025-05-15
Form Type: 424B3
Source: 0001213900-25-044417
Chunk: 312

Company: Profusa, Inc.
Filing Date: 2025-05-15
Form: 424B3
Chunk 312
---
. The officers and directors of NorthView have substantial experience in evaluating the operating and financial merits of companies from a wide range of industries but specifically focusing on the healthcare industry and concluded that their experience and background, together with the experience of their advisors including Marshall & Stevens, enabled them to make the necessary analyses and determinations regarding the Merger. The NorthView Board considered a number of factors pertaining to the Business Combination as generally supporting its decision to enter into the Merger Agreement and the transactions contemplated thereby, including, but not limited to, the following: (i)Late -stagedevelopment or revenue generating (ii)High growth prospects with sustainable proprietary position (iii)Experienced management teams with previous successes, especially where we can add critical public company expertise (iv)Addressable conditions that are clinically important and under -diagnosedor treated (v)Independent companies or corporate spin offs (vi)Domestic or International base of business 160 Profusa meets many of the criteria listed above, including its ability to generate revenue from the Lumee Oxygen product in Europe without further regulatory approval and the potential to generate revenue from Lumee Oxygen product in the U.S. and the Lumee Glucose product in both Europe and the U.S. following regulatory approval, its growth plan to be a leading digital health technology company, its experienced management team, its clinically important consumer -friendlyplatform, its private independent structure, and its potential domestic and international base of business. More specifically, the NorthView Board took into consideration the following factors or made the following determinations, as applicable: (i) A target company in the health care sector with near term revenue potential: Profusa’s biosensor technology and developed applications have been validated and O2 approved in EU while seeking FDA approval in US. Thus, near -termrevenue potential, subject to regulatory approval. (ii) High growth prospects:In addition to oxygen and glucose monitoring, Profusa’s biosensor technology and AI monitoring is a true platform with meaningful revenue growth prospects. The Lumee Oxygen product is ready to be launched in the EU without further regulatory approval. (iii) Proven and experienced management team that is positioned to successively lead New Profusa after the Merge:Profusa is led by Ben Hwang, PhD and co -founder. Ben has a team that has been working effectively together for more than nine years. (iv) Technology that is more than a single application and has the potential to be a platform:The Profusa biosensor platform is clinically important, consumer -friendly